HGD and alkaptonuria: Due to the diversity of homogentisate 1,2-dioxygenase mutations in AKU, a personalized approach to gene therapy is probably not feasible.[20] Some studies[3,6,12] showed that the method of treating AKU depends on the patients, symptoms and genes; however, enzyme replacement therapies remain in the future.